Skip to content
‹ Back to IndustriesHealthcare

A zero-paid claim line is not automatically an underpayment

A zero payment on a claim line isn't automatically an underpayment; contract terms, particularly packaging rules, determine whether zero is correct. Chasing unsupported findings damages credibility with payers and weakens the position of legitimate disputes, so revenue cycle teams must verify the full contract terms and effective dates before treating any payment difference as a finding.

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

By Elizabeth Venafro · Claim PaymentContract TermsRevenue CycleUnderpayment
Share

Key takeaways

01

When a contract packages add-ons into the primary procedure, the add-on line may legitimately show zero payment because it is folded into the primary procedure reimbursement.

02

Pursuing payment differences that lack contract support burns credibility with payers and can weaken the team’s position on later disputes, including valid ones.

03

Always verify the complete contract terms, fee schedules, carve-outs, amendments, and the specific version in effect on the date of service before treating a payment variance as a recoverable underpayment.

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

A decompression line on a surgery center's facility claim paid zero. A zero payment on a claim line can look like missing revenue, and at first glance this one looks like an underpayment. It isn't. That surgery center's contract packages add-ons into the primary procedure, so under those terms zero is the correct separate payment.

That example sits at the center of RSK's clip "why a variance is not automatically a recoverable underpayment." The lesson is specific: a payment difference, including a zero-paid line, is not enough on its own to establish an underpayment. The contract decides whether the first impression holds.

A payment difference isn't proof. Your contract is. — RSK, "why a variance is not automatically a recoverable underpayment"

Why zero can be the right answer

Packaging changes what a zero means. When a contract packages add-ons into the primary procedure, payment for the add-on is folded into what the primary procedure pays. The add-on line can then show nothing on its own while the claim is still paid as agreed.

That is what happened with the decompression line. Read in isolation, the line looks like a miss. Read against the surgery center's contract, it is the expected outcome. As the speaker puts it, "So zero is actually the right answer." Nothing on the remittance alone would tell a reviewer that. Only the contract terms do.

Chasing the wrong line costs more than time

The speaker's warning is about what happens if someone pursues that line anyway. Chase it, and you burn credibility with the payer on a claim you were wrong about from the start. In the speaker's words, "that credibility is an asset."

For a revenue cycle team, the point is that an unsupported finding doesn't just fail by itself. If a payer has already seen findings that the contract didn't back up, every later dispute starts from a weaker position, including the ones that are valid. So a wrong finding costs more than the time spent on one claim.

Check the complete terms and the effective date

Before treating a difference as a finding, the speaker recommends pulling the full set of terms that govern the claim, not just the rate sheet:

  • The full payer contract
  • Every fee schedule term
  • Carve-outs
  • Amendments
  • Which version was in effect on the date of service

The last item is where reviews often go wrong. The clip makes the timing issue simple: a rate that changed in March does not apply to a January claim, even if the reviewer has the newer rate in hand. A variance measured against the wrong version of the contract isn't a variance at all.

Before any variance becomes a finding, ask one question: which version of the contract, with which amendments and carve-outs, was effective on the date of service? If you can't answer it, the finding isn't ready.

The practical order is to verify the terms that applied first, then decide whether the payment departed from them. In the surgery center example, that review explains the zero payment instead of supporting a recovery claim. The zero turned out to be the contract working as written.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Healthcare Insights

Denials get a queue, underpayments just look like paid claims

Denials get a queue, underpayments just look like paid claims

Underpayments in healthcare revenue cycle operations lack the visibility of denied claims because they don't trigger alerts or queue workflows. Without dedicated ownership and line-level verification against contract terms, paid claims that fall short of their contractual amount pass through undetected.

  • 01Denial workflows activate on rejection events, but underpayments produce no event, leaving paid claims unverified by default.
  • 02The speaker says many provider groups lack line-level contract intelligence to check each paid line against the applicable terms.
  • 03Payment received and payment checked are separate tasks: one verifies acceptance, the other verifies correctness—and the second often has no assigned owner.

Nov 6, 2026

A clean, paid, closed claim can still be short of the contract

A clean, paid, closed claim can still be short of the contract

Practices can receive payment on closed, clean claims that still fall short of negotiated contract amounts because billing ends at coding, submission and posting, while no role owns checking whether payer payments match fee schedules. The speaker argues that contract-level payment review is a separate, complementary function that compares closed claims to contract terms and, run continuously, helps surface shortfalls in time to act within timely filing windows.

  • 01Correctly coded and billed healthcare claims can still result in underpayment.
  • 02Practices should review closed-claim payments against contract terms to spot underpayments.
  • 03Discrepancies in claim payments can persist despite adherence to billing protocols.

Nov 6, 2026

Moderna swings to a profit and raises its 2026 revenue outlook as newer vaccines gain traction

Moderna swings to a profit and raises its 2026 revenue outlook as newer vaccines gain traction

Moderna reported third-quarter revenue of $1.31 billion, up 29%, and net income of $162 million, compared with a $200 million loss a year earlier. International COVID vaccine sales under long-term government partnerships and the full-year impact of its next-generation COVID vaccine drove growth, while lower costs helped the profit. The company raised its 2026 revenue growth outlook to 15% to 25% from up to 10%. Its flu shot, mFLUSIVA, was approved in the U.S. and will have a limited U.S. launch in 2026.

  • 01Third-quarter revenue rose 29% to $1.31 billion, with $780 million in the U.S. and $533 million internationally.
  • 02Net income was $162 million, or 38 cents per share, versus a $200 million loss a year earlier.
  • 03Moderna now expects 2026 revenue growth of 15% to 25%, up from up to 10%.

Nov 6, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

About the Expert

EV
Elizabeth Venafro

Fractional CMO

RSK

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512